Common use of Joint Press Release Clause in Contracts

Joint Press Release. Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. Xxxxxx Xxxxxxxx and Paratek Pharmaceuticals Sign Collaboration Agreement for Novel, Narrow-Spectrum Agents for Acne and Rosacea FAJARDO, Puerto Rico and BOSTON, Mass., July 9, 2007 - Xxxxxx Xxxxxxxx Company, Inc. and Paratek Pharmaceuticals, Inc. announced today that the two companies have entered into an exclusive license agreement for the development and commercialization of novel, narrow-spectrum tetracyclines for the treatment of acne and rosacea. Tetracycline antibiotics are the leading approved systemic treatments of moderate to severe inflammatory acne. Discovered decades ago as broad-spectrum systemic antibiotics, tetracyclines have been shown to be potent anti-acne agents. Paratek has utilized its expertise in chemistry to develop novel narrow-spectrum antibacterial tetracyclines with improved anti-inflammatory activity, tolerability and other properties for the next generation treatment of acne and rosacea. These compounds represent the first tetracycline-derived new molecular entities ever to be synthesized specifically as improved therapeutics for dermatologic diseases. “We look forward to a productive collaboration with Paratek as we work together to progress Paratek’s novel tetracycline products through the development process and into commercialization” said Xxxxx Xxxxxxxxxxxxx, Chief Executive Officer and President of Xxxxxx Xxxxxxxx. “We are pleased to announce our collaboration with Xxxxxx Xxxxxxxx, a proven leader in the development and commercialization of dermatology products,” said Xxxxxx X. Xxxx, M.D., Co-founder and Chief Scientific Officer of Paratek Pharmaceuticals. “For years, dermatologists have sought therapies with a more targeted spectrum of activity. While effective, currently marketed tetracyclines possess antibacterial activity against a broad number of organisms not associated with acne or rosacea, which can lead to adverse consequences such as resistance development among life-threatening bacteria and persistent side effects. Paratek’s proprietary compounds have been designed to circumvent these issues by better targeting the causative bacteria and retaining potent anti-inflammatory properties.” Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. Under the terms of the agreement, Xxxxxx Xxxxxxxx will assume responsibility for clinical development of the tetracycline derivative products and will have exclusive rights to market the products in the United States. Paratek received an up-front payment and will be eligible to receive additional payments upon achievement of certain development and regulatory approval milestones. Xxxxxx Xxxxxxxx will pay a royalty to Paratek on sales of any product under the agreement. The leading candidate under the agreement is in preclinical development and expected to enter clinical development in 2008. Xxxxxx Xxxxxxxx Company Inc. is a subsidiary of Xxxxxx Xxxxxxxx Limited (Nasdaq: WCRX).

Joint Press Release. Portions Contacts: The Medicines Company Alnylam Pharmaceuticals, Inc. Michael XxxxxxxlHead of this ExhibitGlobal Communicxxxxxx000-000-0000xxxxxxx.xxxxxxxx@xxxxxxxx.xxx Xxxxxxx XxxxxxxVice President, indicated by Investor Relations and Corporate Communications617-551-8207 Amanda Sxxxxxx (Xxxxx)Spectrum202-955-6222 x2597 DRAFT - Not for Release The Medicines Company and Alnylam Form Strategic Alliance to Develop and Commercialize RNAi Therapeutics Targeting PCSK9 for the xxxx “[***],” were omitted Treatment of Hypercholesterolemia The Medicines Company Obtains Exclusive Global License to Advance ALN-PCS RNAi Therapeutic Program Alnylam to Receive $25 Million in Upfront Payment in Addition to Milestone Payments and have been filed separately with the Secretary of the Commission pursuant Royalties on Product Sales Companies to the Registrant’s application requesting confidential treatment pursuant Host Conference Call Today at 8:30 a.m. ET to Rule 406 of the Securities Act of 1933Discuss Collaboration Parsippany, as amended. Xxxxxx Xxxxxxxx N.J. and Paratek Pharmaceuticals Sign Collaboration Agreement for Novel, Narrow-Spectrum Agents for Acne and Rosacea FAJARDO, Puerto Rico and BOSTONCambridge, Mass., July 9February 4, 2007 2013 - Xxxxxx Xxxxxxxx Company, Inc. The Medicines Company (Nasdaq: MDCO) and Paratek Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the two companies they have entered into formed an exclusive license agreement global alliance for the development and commercialization of novel, narrowAlnylam's ALN-spectrum tetracyclines PCS RNAi therapeutic program for the treatment of acne hypercholesterolemia. “This new alliance unites two organizations with a shared culture and rosaceacommitment to innovation. Tetracycline antibiotics are In my view and past experience, there could be no stronger partner for our ALN-PCS program than The Medicines Company, which has demonstrated industry-wide leadership in the leading approved systemic treatments advancement of moderate cardiovascular medicines to severe inflammatory acnepatients and remarkable success in its strategy of in-licensing, developing, and commercializing breakthrough products,” said John Marxxxxxxx, Xx.X., Chief Executive Officer of Alnylam. Discovered decades ago as broad“For Alnylam, this new partnership enables the advancement of ALN-spectrum systemic antibioticsPCS, tetracyclines have been shown to be potent antian important program within our 'Alnylam 5x15' product development and commercialization strategy focused on RNAi therapeutics directed toward genetically validated targets. We believe that the ALN-acne agents. Paratek has utilized its expertise in chemistry to develop novel narrow-spectrum antibacterial tetracyclines with improved anti-inflammatory activity, tolerability and other properties PCS program holds great promise for the next generation treatment development of acne a significant therapeutic option for patients with hypercholesterolemia, and rosaceathat the unique mechanism of action for ALN-PCS could provide a differentiated and potentially best-in-class strategy for PCSK9 antagonism.” “Our focus on acute and intensive care medicine has led us to a leadership position with Angiomax and potentially with cangrelor in the management of patients in extreme risk as a consequence of the rupture of their vulnerable coronary artery plaque at and around the time of acute coronary syndromes. These compounds represent Meantime, we have made progress with MDCO-216 (ApoA-1 Milano), a turbocharged form of HDL-C ('good cholesterol') which has the first tetracycline-derived new molecular entities ever potential to be synthesized specifically as improved therapeutics for dermatologic diseasesmodify disease through reverse cholesterol transport,” said Clive Mexxxxxx, X.X., Ph.D., Chairman and Chief Executive Officer of The Medicines Company. “Now, this exciting collaboration with Alnylam leaders in their field of RNAi adds a second potentially disease modifying approach and more cutting edge technology to our portfolio. We have seen that PCSK9 gene silencing can substantially reduce LDL-cholesterol in patients and has epidemiological and disease mechanisms studies suggest this can further reduce the risks of the world's number one killer, coronary artery disease. Clearly we see the complementarity of approaches which increase 'good cholesterol' (HDL-C) and decrease 'bad cholesterol' (LDL-C). We look forward to working with our colleagues at Alnylam for whom we have the greatest respect and admiration based upon earlier collaborations particularly around Angiomax, which was invented by John Marxxxxxxx.” XCSK9 (proprotein convertase subtilisin/kexin type 9) is a productive collaboration protein that regulates low-density lipoprotein (LDL) receptor levels on hepatocytes; gain-of-function human mutations in PCSK9 are associated with Paratek as we work together hypercholesterolemia while loss-of-function mutations are associated with lower levels of LDL cholesterol and a reduced risk of cardiovascular disease. ALN-PCS is a PCSK9 synthesis inhibitor that reduces intracellular and extracellular levels of PCSK9 resulting in lowered plasma levels of LDL-C. MDCO-216 is a naturally occurring variant of a protein found in high-density lipoprotein, or HDL. It is a reverse cholesterol transport agent designed to progress Paratek’s novel tetracycline products through the development process and into commercialization” said Xxxxx Xxxxxxxxxxxxx, Chief Executive Officer and President of Xxxxxx Xxxxxxxx. “We are pleased to announce our collaboration with Xxxxxx Xxxxxxxx, a proven leader in the reduce atherosclerotic plaque burden development and commercialization thereby reduce the risk of dermatology products,” said Xxxxxx X. Xxxxadverse thrombotic events. Under this alliance, M.D., Co-founder The Medicines Company and Chief Scientific Officer of Paratek Pharmaceuticals. “For years, dermatologists have sought therapies with a more targeted spectrum of activity. While effective, currently marketed tetracyclines possess antibacterial activity against a broad number of organisms not associated with acne or rosacea, which can lead Alnylam intend to adverse consequences such as resistance development among life-threatening bacteria and persistent side effects. Paratek’s proprietary compounds have been designed to circumvent these issues by better targeting collaborate on the causative bacteria and retaining potent anti-inflammatory properties.” Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary advancement of the Commission pursuant ALN-PCS program. Alnylam's ALN-PCS program includes ALN-PCS02 an intravenously administered RNAi therapeutic which has completed a Phase I trial, and ALN-PCSsc a subcutaneously administered RNAi therapeutic currently in pre-clinical development. Alnylam will continue the program while funded by The Medicines Company for an estimated one to two years to complete certain pre-clinical and Phase I clinical studies. The Medicines Company will then lead and fund development from Phase II forward and commercialize the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amendedALN-PCS program if successful. Under the terms of the agreement, Xxxxxx Xxxxxxxx The Medicines Company will assume responsibility for clinical make an upfront cash payment of $25 million to Alnylam. Alnylam may also receive potential development and commercial milestone payments of the tetracycline derivative products and will have exclusive rights up to market the products in the United States$180 million. Paratek received an up-front payment and Alnylam will be eligible to receive additional payments upon achievement of certain development and regulatory approval milestones. Xxxxxx Xxxxxxxx will pay a royalty to Paratek scaled double-digit royalties on global products sales of any product under ALN-PCS products. Alnylam has completed a Phase I trial of ALN-PCS02 in healthy volunteer subjects with elevated baseline LDL-C. Results showed that administration of a single intravenous dose of drug, in the agreementabsence of concomitant lipid-lowering agents such as statins, resulted in statistically significant and durable reductions of PCSK9 plasma levels of up to 84% and lowering of LDL-C of up to 50%. ALN-PCS02 was shown to be generally safe and well tolerated in this study and there were no serious adverse events related to study drug administration. Alnylam has also presented pre-clinical data from its ALN-PCSsc program 66 demonstrating potent knockdown of the PCSK9 target gene with an ED50 of less than 0.3 mg/kg after a single subcutaneous dose. “Cardiovascular disease remains the leading cause of mortality worldwide, with elevated LDL-C a major modifiable risk factor. New strategies are needed to dramatically and rapidly reduce LDL-C and prevent acute cardiovascular events that result from the rupture of cholesterol rich plaque when patients are at their most vulnerable,” said Daniel J. Xxxxx, X.X., professor of Medicine and chief, Division of Translational Medicine and Human Genetics, at the Perelman Xxxxxx of Medicine at the University of Pennsylvania. “As a key regulator of the LDL receptor, liver-expressed PCSK9 is one of the most important and best validated new targets in molecular medicine for the treatment of hypercholesterolemia. The leading candidate under ALN-PCS data generated to date are very encouraging and I look forward to continued clinical studies that highlight the agreement is in preclinical development and expected to enter clinical development in 2008. Xxxxxx Xxxxxxxx Company Inc. is a subsidiary unique mechanistic approach of Xxxxxx Xxxxxxxx Limited (Nasdaq: WCRX)PCSK9 synthesis inhibitors.”

Joint Press Release. Portions PRESS RELEASE GE Healthcare and Geron announce exclusive global agreement to commercialize stem cell drug discovery technologies CHALFONT ST XXXXX, UK & MENLO PARK, CALIFORNIA, 30 JUNE 2009 - GE Healthcare, a unit of General Electric Company (NYSE: GE), and Geron Corporation (Nasdaq: GERN) today announced that they have entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening. Financial terms are not being disclosed. “This agreement marks a further step in GE Healthcare’s cell technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and therapy markets,” said Xxxxxxxxxx Xxxxxxx, General Manager, Cell Technologies, GE Healthcare. “Combining GE Healthcare’s reach into the drug discovery and research markets as well our expertise in cell manufacturing with Geron’s expertise and IP in hESCs, means that together, we will be able together to accelerate the development of hESC-derived products for drug discovery and development.” “Geron is intensely focused on developing hESC-based cell therapies, and the expertise that we have developed in scalable manufacturing and differentiation of hESCs to specific cell types is directly applicable to the production of these cells for drug discovery,” said Xxxxx X. Xxxx, X.X., Ph.X. Xxxxx’x Senior Vice President of Business Development and Chief Patent Counsel. “In GE Healthcare we have found the ideal partner with whom to develop this Exhibitnear-term commercial opportunity. There is much anticipation of the availability of hESC-derived cells for drug discovery applications within the pharmaceutical industry and we look forward to working closely with GE Healthcare to deliver these promising products.” Under the terms of the agreement, indicated GE Healthcare has been granted an exclusive license under Geron’s extensive intellectual property portfolio covering the growth and differentiation of hESCs, as well as a sublicense under Geron’s rights to the foundational hESC patents held by the xxxx “[***],” were omitted Wisconsin Alumni Research Foundation. GE Healthcare and Geron have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. Xxxxxx Xxxxxxxx and Paratek Pharmaceuticals Sign Collaboration Agreement for Novel, Narrowestablished a multi-Spectrum Agents for Acne and Rosacea FAJARDO, Puerto Rico and BOSTON, Mass., July 9, 2007 - Xxxxxx Xxxxxxxx Company, Inc. and Paratek Pharmaceuticals, Inc. announced today that year alliance program under which scientists from the two companies have entered into an exclusive license agreement will work closely together to develop hESC-based products for drug discovery. The program will use stem cells derived from hESC lines listed on the NIH Human Pluripotent Stem Cell Registry. GE Healthcare will fund the R&D program and will be responsible for manufacturing, sales and distribution of products developed under the agreement. 57 of 61 GEH-02948/Exclusive License and Alliance Agreement/GE Healthcare UK Limited Up to three quarters of toxicity problems are not detected until preclinical or later stages of drug development and commercialization this significantly increases the cost of noveldeveloping new drugs. Earlier detection of toxicity problems could reduce both overall drug development costs and potentially harmful patient exposure in clinical trials. The GE Healthcare – Geron alliance will develop cellular assay products derived from hESCs that could be used in early in vitro screening of drug candidates. Cells derived from hESCs have similar attributes to their counterparts in the body, narrow-spectrum tetracyclines for the treatment and can therefore be used to predict many pharmacological characteristics of acne a drug candidate. Cardiotoxicity and rosacea. Tetracycline antibiotics hepatotoxicity are the leading approved systemic treatments most common causes of moderate drug safety liabilities and withdrawal of drugs during development. Derivation of functional cell types from hESCs, in particular hepatocytes of the liver and cardiomyocytes of the heart, could provide a reliable supply of cells to severe inflammatory acneperform metabolism, biodistribution and toxicity testing of drug candidates. Discovered decades ago as broadThe combination of GE Healthcare’s Cell Factory capability for cell reproduction and manufacturing with Geron’s hESC technology makes it possible to generate a large scale supply of hESC-spectrum systemic antibiotics, tetracyclines have been shown derived cells which retain normal cellular functions and could address bottlenecks in new drug research and accelerate the drug development process. The first products developed in the GE Healthcare and Geron alliance are expected to be potent anti-acne agents. Paratek has utilized its expertise in chemistry to develop novel narrow-spectrum antibacterial tetracyclines with improved anti-inflammatory activityavailable by early 2010, tolerability and other properties for the next generation treatment of acne and rosacea. These compounds represent the first tetracycline-derived new molecular entities ever to be synthesized specifically as improved therapeutics for dermatologic diseases. “We look forward to a productive collaboration with Paratek as we work together to progress Paratek’s novel tetracycline products through the development process and into commercialization” said Xxxxx Xxxxxxxxxxxxx, Chief Executive Officer and President of Xxxxxx Xxxxxxxx. “We are pleased to announce our collaboration with Xxxxxx Xxxxxxxx, a proven leader in the development and commercialization of dermatology products,” said Xxxxxx X. Xxxx, M.D., Co-founder and Chief Scientific Officer of Paratek Pharmaceuticals. “For years, dermatologists have sought therapies with a more targeted spectrum pipeline of activity. While effective, currently marketed tetracyclines possess antibacterial activity against a broad number of organisms not associated with acne or rosacea, which can lead products to adverse consequences such as resistance development among life-threatening bacteria and persistent side effects. Paratek’s proprietary compounds have been designed to circumvent these issues by better targeting the causative bacteria and retaining potent anti-inflammatory properties.” Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amendedfollow. Under the terms of the agreement, Xxxxxx Xxxxxxxx intellectual property rights arising from the alliance program research will assume responsibility be shared, with GE Healthcare receiving rights for clinical the development of drug discovery technologies, and Geron receiving rights for cellular therapies applications. ----------------ends------------------ About GE Healthcare GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the tetracycline derivative products world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and will have exclusive rights to market improving quality and efficiency around the products world. Headquartered in the United StatesKingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Paratek received an upWorldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at xxx.xxxxxxxxxxxx.xxx. 58 of 61 GEH-02948/Exclusive License and Alliance Agreement/GE Healthcare UK Limited About Xxxxx Xxxxx is a biopharmaceutical company that is developing first-front payment in-class therapeutic products for the treatment of cancer and will be eligible chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The products are based on our core expertise in telomerase and human embryonic stem cells. For more information about Geron, visit xxx.xxxxx.xxx. Safe Harbor This news release may contain forward-looking statements made pursuant to receive additional payments upon achievement the “safe harbor” provisions of certain the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release regarding potential applications of Geron’s human embryonic stem cell technology constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approval milestonesapprovals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Xxxxxx Xxxxxxxx will pay a royalty Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to Paratek time in Geron’s periodic reports, including the annual report on sales Form 10-Q for the quarter ended March 31, 2009. Contact GE Healthcare: Geron: Xxxxx XxXxxxxxx Xxxx Xxxxxxxxxx Media Relations Investor and Media Relations xxxxx.xxxxxxxxx@xx.xxx xxxx@xxxxx.xxx +44 771 751 7028 650-473-7765 59 of any product under the agreement. The leading candidate under the agreement is in preclinical development 61 GEH-02948/Exclusive License and expected to enter clinical development in 2008. Xxxxxx Xxxxxxxx Company Inc. is a subsidiary of Xxxxxx Xxxxxxxx Alliance Agreement/GE Healthcare UK Limited (Nasdaq: WCRX).SCHEDULE 7.1.1